Table II.
General characteristics of patients undergoing HSCT
| Characteristics | Overall, No.= 85 |
|---|---|
|
| |
| Age, median (range) | 48 (5, 69) |
|
| |
| Gender, No. (%) | |
| Female | 36 (42%) |
| Male | 49 (58%) |
|
| |
| Diagnosis, No. (%) | |
| Lymphoproliferative disorder | 25 (29%) |
| Myeloproliferative disorder | 59 (69%) |
| Aplastic anemia | 1 (1.2%) |
|
| |
| Donor, No. (%) | |
| Haplo | 26 (31%) |
| MUD- MMUD | 55 (65%) |
| Sibling | 4 (4.7%) |
|
| |
| HLA match, No. (%) | |
| MUD 10/10 | 34 (40%) |
| MMUD 9/10 | 21 (24.7%) |
| Haplo | 26 (30.6%) |
| Sibling | 4 (4.7%) |
|
| |
| ABO, No. (%) | |
| Matched, No. (%) | 42 (49%) |
| Major MM, No. (%) | 15 (18%) |
| Minor MM, No. (%) | 23 (27%) |
| Bidirectional MM, No. (%) | 5 (5.9%) |
|
| |
| HSC source, No. (%) | |
| BM | 21 (25%) |
| PBSC | 59 (69%) |
| PBSC cryopreserved | 5 (5.9%) |
|
| |
| Sorror, No. (%) | |
| 0–2 | 67.2% |
| 3–4 | 26.4% |
| 5–6 | 6% |
|
| |
| Conditioning regimen, No. (%) | |
| MAC | 56 (66%) |
| RIC | 29 (34%) |
|
| |
| Graft manipulation, No. (%) | |
| No manipulation | 38 (45%) |
| Plasma-depletion | 40 (47%) |
| Plasma-depletion + HES | 2 (2.4%) |
| Plasma-depletion + cryopreservation | 2 (2.4%) |
| Cryopreservation | 3 (3.5%) |
|
| |
| Donor gender, No. (%) | |
| Female | 32 (38%) |
| Male | 53 (62%) |
|
| |
| Donor age, median (range) | 33 (19–67) |
|
| |
| GvHD prophylaxis, No. (%) | |
| ATG+CyA+MTX | 57 (67%) |
| CyA+MMF+PTCy | 26 (31%) |
| CyA+MTX | 2 (2.4%) |